Adenosine-5-Diphosphoribose | 20762-30-5

• 物质功能分类: 生物 - ELISA 试剂盒
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: Adenosine-5-Diphosphoribose
• 英文别名: Adenosine diphosphate ribose；[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] (3,4,5-trihydroxyoxolan-2-yl)methyl hydrogen phosphate
• CAS: 20762-30-5
• 化学式: C₁₅H₂₃N₅O₁₄P₂
• 分子量: 559.32
• InChiKey: SRNWOUGRCWSEMX-UHFFFAOYSA-N

物化性质

• 沸点：
  1007.5±75.0 °C(Predicted)
• 密度：
  2.24±0.1 g/cm3(Predicted)
• 物理描述：
  Solid
• 碰撞截面：
  212.4 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

计算性质

• 辛醇/水分配系数(LogP)：
  -6.1
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  292
• 氢给体数：
  8
• 氢受体数：
  18

文献信息

• POLYMORPHS OF RUCAPARIB CAMSYLATE AND METHODS OF MAKING SAME
  申请人：RK Pharma Solutions LLC

  公开号：US20190233428A1

  公开（公告）日：2019-08-01

  Novel polymorphs of rucaparib camsylate include Form alpha having XRPD peaks at diffraction angles (2θ) of 6.14±0.2, 12.41±0.2, 15.34±0.2, 15.95±0.2, 16.36±0.2, 16.51±0.2 and 19.67±0.2, Form beta having XRPD peaks at diffraction angles (2θ) of 6.86±0.2, 9.58±0.2, 12.75±0.2, 14.56±0.2, 15.05±0.2, 20.76±0.2 and 22.45±0.2, and Form gamma having XRPD peaks at diffraction angles (2θ) of 9.5±0.2, 12.73±0.2, 14.77±0.2, 15.16±0.2, 20.62±0.2, 22.33±0.2, 22.63±0.2 and 27.29±0.2. Methods are disclosed for the preparation of such polymorphic forms and pharmaceutical compositions containing such polymorphic forms. A method is disclosed for preparing a highly pure Form B of rucaparib camsylate. Pharmaceutical compositions containing highly pure Form B prepared by the method are disclosed.

  鲁卡帕尼坎西酸盐的新型多晶形包括α型，其XRPD峰位于衍射角度（2θ）为6.14±0.2、12.41±0.2、15.34±0.2、15.95±0.2、16.36±0.2、16.51±0.2和19.67±0.2；β型，其XRPD峰位于衍射角度（2θ）为6.86±0.2、9.58±0.2、12.75±0.2、14.56±0.2、15.05±0.2、20.76±0.2和22.45±0.2；和γ型，其XRPD峰位于衍射角度（2θ）为9.5±0.2、12.73±0.2、14.77±0.2、15.16±0.2、20.62±0.2、22.33±0.2、22.63±0.2和27.29±0.2。公开了制备这些多晶形式和含有这些多晶形式的药物组合物的方法。还公开了制备高纯度B型鲁卡帕尼坎西酸盐的方法。公开了含有通过该方法制备的高纯度B型的药物组合物。
• Polymorphs of rucaparib camsylate and methods of making same
  申请人：RK Pharma Solutions LLC

  公开号：US10442813B2

  公开（公告）日：2019-10-15

  Novel polymorphs of rucaparib camsylate include Form alpha having XRPD peaks at diffraction angles (2θ) of 6.14±0.2, 12.41±0.2, 15.34±0.2, 15.95±0.2, 16.36±0.2, 16.51±0.2 and 19.67±0.2, Form beta having XRPD peaks at diffraction angles (2θ) of 6.86±0.2, 9.58±0.2, 12.75±0.2, 14.56±0.2, 15.05±0.2, 20.76±0.2 and 22.45±0.2, and Form gamma having XRPD peaks at diffraction angles (2θ) of 9.5±0.2, 12.73±0.2, 14.77±0.2, 15.16±0.2, 20.62±0.2, 22.33±0.2, 22.63±0.2 and 27.29±0.2. Methods are disclosed for the preparation of such polymorphic forms and pharmaceutical compositions containing such polymorphic forms. A method is disclosed for preparing a highly pure Form B of rucaparib camsylate. Pharmaceutical compositions containing highly pure Form B prepared by the method are disclosed.

  Rucaparib camsylate 的新型多晶型包括形式 alpha，其 XRPD 峰的衍射角 (2θ) 为 6.14±0.2、12.41±0.2、15.34±0.2、15.95±0.2、16.36±0.2、16.51±0.2 和 19.67±0.2；形式 beta，其 XRPD 峰的衍射角 (2θ) 为 6.86±0.2、9.58±0.2、12.75±0.2、14.56±0.2、15.05±0.2、20.76±0.2 和 22.45±0.2。86±0.2、9.58±0.2、12.75±0.2、14.56±0.2、15.05±0.2、20.76±0.2 和 22.45±0.2，形态 γ 的 XRPD 峰衍射角（2θ）为 9.5±0.2、12.73±0.2、14.77±0.2、15.16±0.2、20.62±0.2、22.33±0.2、22.63±0.2 和 27.29±0.2。公开了制备此类多晶型和含有此类多晶型的药物组合物的方法。公开了一种制备高纯度 B 形芦卡帕利 camsylate 的方法。公开了含有通过该方法制备的高纯度形式 B 的药物组合物。
• US9926340B2
  申请人：——

  公开号：US9926340B2

  公开（公告）日：2018-03-27
• [EN] COMBINATION THERAPY FOR TREATING CANCER<br/>[FR] POLYTHÉRAPIE POUR LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2021224381A1

  公开（公告）日：2021-11-11

  Disclosed are methods of treating cancer comprising administering to a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of AZD2811 nanoparticles and an effective amount of olaparib.